Want to see TRVI full AI Analyst Report?
TRVI Stock Chart & Stats
$13.47
<$0.01(0.12%)
At close: 4:00 PM EST
$13.47
<$0.01(0.12%)
Day’s Range― - ―
52-Week Range$8.04 - $20.22
Previous CloseN/A
Volume226.18K
Average Volume (3M)1.45M
Market Cap
$2.13B
Enterprise Value$2.60K
Total Cash (Recent Filing)$318.87M
Total Debt (Recent Filing)$605.00K
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding142,475,850
10 Day Avg. Volume1,525,610
30 Day Avg. Volume1,450,272
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)9.91
Price to Sales (P/S)0.00
P/FCF Ratio-43.15
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.08
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.00Price Target Upside115.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.48
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low leverage gives Trevi a stronger balance-sheet cushion, reducing fixed financial obligations and preserving flexibility to fund development or absorb delays while Haduvio remains investigational. This provides durable financial support for continued clinical execution.
Growing Equity BaseMaterial growth in equity and assets has strengthened Trevi’s financial resources and improved flexibility for ongoing development. A larger capital base can help support clinical programs and extend strategic options, even though the company remains loss-making.
Focused Lead ProgramTrevi has a clearly defined development focus in Haduvio and is evaluating the same lead candidate across chronic cough and pruritus. Concentrating resources around one investigational platform may support coherent clinical execution and potential indication expansion.
Bears Say
Pre-Revenue ModelWith no reported revenue, Trevi has not yet established a commercial income stream to support operations. The business therefore remains dependent on successful clinical development and eventual regulatory approval before product sales can begin.
Persistent Net LossesPersistent, sizable net losses indicate that Trevi’s current operations consume substantial resources before generating commercial returns. The wider TTM loss versus 2025 suggests expenses remain elevated, increasing the distance to sustainable profitability.
Negative Cash GenerationOngoing negative operating cash flow means Trevi cannot currently fund development from internally generated cash. Continued consumption increases reliance on external financing and can constrain planning if funding needs persist while Haduvio remains unapproved.
Trevi Therapeutics News
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $8.04 and its highest was $20.22 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Trevi Therapeutics Inc’s market cap is $2.13B.
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Nov 11, 2026 which is in 50 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.109 by -$0.001.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -0.13.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 142,475,850 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.109. Following the earnings report the stock price went up 0.054%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Currently, no hedge funds are holding shares in TRVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trevi Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (115.29% Upside)
$29.00 (115.29% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
58.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
TRVI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid execution progress: a strengthened balance sheet (pro forma cash ~ $334M) with runway into 2030, positive FDA alignment for IPF-related chronic cough, near-term trial initiations (Phase III IPF, Phase IIb RCC), an adaptive plan for non-IPF-ILD pending FDA agreement, expansion of IP filings and active scientific visibility (ATS, Investor Day). Principal risks discussed include competitor P2X3 readouts, possible trial upsizing via SSRE (and associated costs/timing), placebo variability in RCC, and regulatory dependence for the non-IPF-ILD program. On balance, the company presented multiple material positives and manageable risks tied to execution and external competitive/regulatory factors.View all TRVI earnings summariesTRVI Stock 12 Month Forecast
Average Price Target
$29.00
▲(115.29% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
1.31% Insiders
16.75% Mutual Funds
56.60% Other Institutional Investors
14.74% Public Companies and
Individual Investors